Hannah Jebens

Hannah Jebens

Auto-generated profile, based on publicly available information

Hannah Jebens

Institute of Clinical Molecular Biology, Kiel University and University Hospital Schleswig-Holstein, Kiel, Germany

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
KMKarlis A. Moors
Karlis A. Moors
SWSaskia Weber-Stiehl
Saskia Weber-Stiehl
HJHannah Jebens
Hannah Jebens
BNBram Nap
Bram Nap
DFDaniel Fässler
Daniel Fässler
CKChristoph Kaleta
Christoph Kaleta
Proton pump inhibitors (PPIs) alter the gut microbiome, but the contribution of these changes to systemic effects associated with PPI use remains unclear. Here, we show that PPI-associated microbiome remodelling induces systemic metabolic and transcriptional responses independently of direct drug exposure. Integrating human microbiome and metabolomics data with metabolic modelling, we identified consistent alterations in microbial metabolic functions and host–microbiome co-metabolism. Transfer of PPI-associated microbiota into germ-free mice reproduced key metabolic changes observed in humans, particularly in aromatic amino acid metabolism, and induced additional alterations in systemic lipid metabolism. These changes were accompanied by tissue-specific transcriptional responses in the colon, liver and brain, affecting metabolic and inflammatory pathways. Together, our findings identify transferable metabolic and transcriptional microbiome-mediated signatures that may contribute to the adverse systemic effects associated with PPI use.